Voclosporin

DB11693ApprovedInvestigationalSmall moleculeCalcineurin Inhibitor Immunosuppressant

Voclosporin is a calcineurin inhibitor for the treatment of lupus nephritis (LN) in patients diagnosed with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE.

Chemical structure of Voclosporin
Mechanism
Curator reviewed · 3 references
Primary indication
Voclosporin is used in combination with a background immunosuppressive regimen for the treatment of lupus nephritis.Curator reviewed · 1 structured indication
Formula / weight
C63H111N11O12 · 1214.646 g/mol (avg)
First approval
United States, 2021 · European Union, 2022
Also known as
Lupkynis
Code names
ISA-247 · ISATX-247 · LX-211 · R 1524
Brand names
  • Lupkynis

Resolves to

Structure
InChIKeyBICRTLVBTLFLRD-PTWUADNWSA-NSMILES[H][C@@]1([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O)C(C)C
Transporters

What you can answer from here — as of September 05, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
659Drug interactionsStructured to mechanism, not free text
Sign in
23Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
5Marketed productsAcross 3 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 19 drug categories
Sign in
22+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Voclosporin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account